| アブストラクト | Thrombocytopenia is a clinically important hematological adverse event associated with several antiseizure medications (ASMs), but comparative real-world evidence across individual drugs and pharmacovigilance databases remains limited. We conducted a retrospective pharmacovigilance study using the US Food and Drug Administration Adverse Event Reporting System (FAERS) from Q1 2004 to Q2 2025, with supportive cross-database comparisons using the Japanese adverse drug event report database and the Canada vigilance adverse reaction database from January 2004 to June 2025. Thrombocytopenia events were identified using the narrow Standardized Medical Dictionary for Regulatory Activities Query "hematopoietic thrombocytopenia." Disproportionality was assessed using the reporting odds ratio and Bayesian confidence propagation neural network, and subgroup, time-to-onset, and univariable logistic regression analyses of reported fatal outcomes were also performed. In FAERS, 4835 reports with ASMs designated as primary suspect drugs were identified, corresponding to 4900 thrombocytopenia events. Positive disproportionality signals were detected for valproic acid, levetiracetam, and carbamazepine. Adults aged >/=65 years had the shortest median time to onset (14 days), and reports with serious outcomes had an earlier onset than reports without a recorded serious outcome (13 vs 29 days). Based on the reporting odds ratio criterion, valproic acid showed positive reporting signals in all 3 databases, whereas levetiracetam showed signals in FAERS and Canada Vigilance Adverse Reaction Database and carbamazepine in FAERS and Japanese adverse drug event report. Overall, this study identified drug-specific thrombocytopenia reporting signals and earlier onset patterns among older adults and reports with serious outcomes. These hypothesis-generating findings warrant further epidemiological evaluation and may inform studies of risk-adapted monitoring; they do not establish incidence, comparative safety, or causality. |
| ジャーナル名 | Medicine |
| Pubmed追加日 | 2026/11/13 |
| 投稿者 | Huang, Jie; Jin, Bao-Fen; Mai, Zhi-Kai; Zhao, Pei-Jin; Zhang, Ru-Meng; Yu, Ling-Yan |
| 組織名 | Department of Pharmacy, Fuyong People's Hospital of Bao'an District, Shenzhen,;Guangdong, China.;Department of Pharmacy, The Second Affiliated Hospital, Zhejiang University;School of Medicine, Hangzhou, Zhejiang, China.;Department of Pharmacy, School of Medicine, The Sixth Affiliated Hospital of;South China University of Technology (Nanhai District People's Hospital of;Foshan), Foshan, China.;Department of Pharmacy, Shenzhen Maternity and Child Healthcare Hospital,;Shenzhen, Guangdong, China.;Department of Pharmacy, Xuzhou Central Hospital, Xuzhou, Jiangsu, China. |
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/43024290/ |